XML 116 R103.htm IDEA: XBRL DOCUMENT v3.7.0.1
EQUITY METHOD INVESTMENTS (Narrative) (Details)
¥ in Thousands, $ in Thousands
1 Months Ended 12 Months Ended
Sep. 29, 2016
CNY (¥)
Sep. 29, 2016
USD ($)
Jul. 31, 2015
CNY (¥)
Dec. 31, 2016
CNY (¥)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
CNY (¥)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
CNY (¥)
Dec. 28, 2012
CNY (¥)
Schedule Of Results Related To Equity Accounted Investees [Line Items]                  
Share of net profit (loss)       ¥ 616 $ 89 ¥ (5,572)   ¥ 13,911  
Cash distribution from an equity investee       9,357 1,348 ¥ 24,316   21,984  
Fair value of identified net asset on acquisition date     ¥ 19,658           ¥ 73,570
Business Combination, Consideration Transferred ¥ 41,670 $ 6,002   ¥ 100,000 $ 14,403        
Suzhou Chorus Medical Technologies Co., Ltd [Member]                  
Schedule Of Results Related To Equity Accounted Investees [Line Items]                  
Equity Method Investment, Ownership Percentage [1]       36.00% 36.00% 36.00% 36.00%    
Business Combination, Consideration Transferred           ¥ 4,320 $ 622    
Global Oncology One, Inc [Member]                  
Schedule Of Results Related To Equity Accounted Investees [Line Items]                  
Equity Method Investment, Ownership Percentage [1]       46.90% 46.90% 46.90% 46.90%    
Business Combination, Consideration Transferred           ¥ 8,679 $ 1,250    
CMSUSA [Member]                  
Schedule Of Results Related To Equity Accounted Investees [Line Items]                  
Equity Method Investment, Ownership Percentage           100.00% 100.00%    
PTC [Member]                  
Schedule Of Results Related To Equity Accounted Investees [Line Items]                  
Share of net profit (loss)     ¥ 34,206           ¥ 107,139
Cash distribution from an equity investee       ¥ 9,357 $ 1,348 ¥ 24,316   ¥ 18,812  
[1] In 2015, the Group entered into two share transfer agreements with JWYK, which was controlled by one of the Group's directors. Pursuant to the agreements, JWYK would acquired 36% equity interest in Suzhou Chorus and 100% interest in China Medstar, an oversea subsidiary of the Company who holds 46.9% equity interest in Global Oncology from the Group, at a consideration of RMB4,320 (US$622) and RMB8,679 (US$1,250) respectively. On April 25, 2016 and November 10, 2016, the Group received full payments from JWYK. As of December 31, 2016, the changes in registration of shareholders have not been completed and the consideration received was recorded in accrued expenses and other liabilities on the consolidated balance sheets (note 19).